We have previously observed that tivantinib, although being indeed a weak MET inhibitor, much more prominently targets GSK3α and GSK3β in NSCLC cells and that inhibition of these targets can explain its potent anticancer activity in NSCLC13. The gene discussed is GSK3B; the disease is non-small cell lung carcinoma.